Education
About Us
Working with TipRanks
Follow Us
Adagene (ADAG)
NASDAQ:ADAG
ADAG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.33 - $3.58
Previous CloseN/A
Volume1.51K
Average Volume (3M)33.13K
Market Cap
$65.48M
Enterprise Value$24.75M
Total Cash (Recent Filing)$92.53M
Total Debt (Recent Filing)$2.56M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Aug 27, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding47,109,554
10 Day Avg. Volume12,874
30 Day Avg. Volume33,126
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.10
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit239.86
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$8.00Price Target Upside475.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Adagene News
PremiumCompany Announcements
Adagene Inc. Reports 2024 Financial Results and Progress
PremiumCompany Announcements
Adagene Reports 2024 Financial Results and Advances Clinical Programs
PremiumCompany Announcements
Adagene Reports Promising Results in Colorectal Cancer Study---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPromising efficacy and favorable safety profiles for ADG126 plus pembrolizumab reinforce the drug's potential in MSS-CRC and other cancer indications approved for anti-CTLA-4 agents.
Financial PositionAdagene had approximately $85M in cash and cash equivalents, which is believed to be sufficient to support operations into 2H26.
Regulatory PathwayKey opinion leaders believe a drug that delivers a high response rate and maintains repeat dosing and durable efficacy in a high percentage of patients is likely to get FDA approval, potentially via an Accelerated Approval pathway.
Bears Say
Development TimelineThe launch timeline of ADG126 has been pushed out from 2028 to 2029, reflecting uncertainty in its development plan.
Market OpportunityAnalyst is moving to the sidelines based on a combination of factors including the relatively small market opportunity, regulatory uncertainty, and safety concerns with targeting CTLA-4.
Regulatory UncertaintyRegulatory uncertainty is a concern as another company is testing a similar immunotherapy combination for a similar treatment.
---
Ownership Overview
―
Insiders
0.02%
Mutual Funds
11.78% Other Institutional Investors
88.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ADAG FAQ
What was Adagene’s price range in the past 12 months?
Adagene lowest stock price was $1.32 and its highest was $3.58 in the past 12 months.
What is Adagene’s market cap?
Adagene’s market cap is $65.48M.
When is Adagene’s upcoming earnings report date?
Adagene’s upcoming earnings report date is Aug 27, 2025 which is in 123 days.
How were Adagene’s earnings last quarter?
Adagene released its earnings results on Mar 24, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.33 by $0.04.
Is Adagene overvalued?
According to Wall Street analysts Adagene’s price is currently Undervalued.
Does Adagene pay dividends?
Adagene does not currently pay dividends.
What is Adagene’s EPS estimate?
Adagene’s EPS estimate is -0.32.
How many shares outstanding does Adagene have?
Adagene has 47,109,554 shares outstanding.
What happened to Adagene’s price movement after its last earnings report?
Adagene reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.33. Following the earnings report the stock price went up 5.357%.
Which hedge fund is a major shareholder of Adagene?
Currently, no hedge funds are holding shares in ADAG
---
Adagene Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (475.54% Upside)
$8.00 (475.54% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.45%
12-Months-Change
Fundamentals
Return on Equity
-55.14%
Trailing 12-Months
Asset Growth
-22.84%
Trailing 12-Months
Company Description
Adagene
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
---
ADAG Stock 12 Month Forecast
Average Price Target
$8.00
▲(475.54% Upside)
Technical Analysis
Adverum Biotechnologies
―
Avalo Therapeutics
―
IGM Biosciences
―
Caribou Biosciences
―
Tenaya Therapeutics
―
Best Analysts Covering ADAG
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
+13.47%
reiterated a buy rating 23 days ago
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +13.47% per trade.
---